Long-term success and follow-up after atrial fibrillation ablation

Current Cardiology Reviews

Volumn 8, Issue 4, 2012, Pages 354-361

  Kircher, S ^a   Hindricks, G ^a   Sommer, P ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Asymptomatic recurrences; Atrial fibrillation; Catheter ablation; Follow up strategies; Implantable cardiac monitors; Success rate

Indexed keywords

ARTICLE; BRAIN ISCHEMIA; CARDIAC PATIENT; CARDIOVASCULAR RISK; CATHETER ABLATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; MORBIDITY; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; SENSITIVITY ANALYSIS; THROMBOEMBOLISM; TREATMENT WITHDRAWAL;

ATRIAL FIBRILLATION; CATHETER ABLATION; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; FORECASTING; HUMANS; POSTOPERATIVE CARE; RECURRENCE; TREATMENT OUTCOME;

EID: 84870198279     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/157340312803760758     Document Type: Article

References (76)

1. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12(10): 1360-420.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/ Paisley study. Heart 2001; 86: 516-21.
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.
4. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006; 119: 448e1-19.
5. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 2009; 11(7): 860-85.
6. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000; 4(2): 369-82.
7. Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 2004; 147(1): 121-6.
8. Fuster V, Rydén LE, Cannom DS et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57(11): e101-98.
9. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98(10): 946-52.
10. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285(22): 2864-70.
11. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. Europace 2012; 14(4): 528-606.
12. Oral H, Morady F. How to select patients for atrial fibrillation ablation. Heart Rhythm 2006; 3(5): 615-8
13. Quirino G, Giammaria M, Corbucci G, et al. Diagnosis of paroxysmal atrial fibrillation in patients with implanted pacemakers: relationship to symptoms and other variables. Pacing Clin Electrophysiol 2009; 32(1): 91-8.
14. Silberbauer J, Veasey RA, Cheek E, Maddekar N, Sulke N. Electrophysiological characteristics associated with symptoms in pacemaker patients with paroxysmal atrial fibrillation. J Interv Card Electrophysiol 2009; 26(1): 31-40.
15. Israel CW, Grönefeld G, Ehrlich JR, Li YG, Hohnloser SH. Longterm risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43(1): 47-52.
16. Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003; 107(12): 1614-9.
17. Strickberger SA, Ip J, Saksena S, Curry K, Bahnson TD, Ziegler PD. Relationship between atrial tachyarrhythmias and symptoms. Heart Rhythm 2005; 2(2): 125-31.
18. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 2009; 11(7): 860-85
19. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007; 9(11): 1006-23.
20. Arya A, Hindricks G, Sommer P, et al. Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients. Europace 2010; 12(2): 173-80.
21. Lee SH, Tai CT, Hsieh MH, et al. Predictors of early and late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. J Interv Card Electrophysiol 2004; 10(3):221-6.
22. Fenelon G, Wijns W, Andries E, Brugada P. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol 1996; 19(1): 95-106.
23. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009; 20(3): 241-8.
24. Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 1985; 254(24): 3449-53.
25. Patten M, Maas R, Karim A, Müller HW, Simonovsky R, Meinertz T. Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: subanalysis of the SOPAT trial. J Cardiovasc Electrophysiol 2006; 17(11):1216-20.
26. Patten M, Maas R, Bauer P, et al. Suppression of paroxysmal atrial tachyarrhythmias-results of the SOPAT trial. Eur Heart J 2004; 25(16): 1395-404.
27. Boriani G, Padeletti L, Santini M, et al. Rate control in patients with pacemaker affected by brady-tachy form of sick sinus syndrome. Am Heart J 2007; 154(1): 193-200.
28. Lévy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999; 99(23): 3028-35.
29. Kerr C, Boone J, Connolly S, et al. Follow-up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J 1996; 17 Suppl C: 48-51.
30. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89(1): 224-7.
31. Page RL, Tilsch TW, Connolly SJ, et al. Asymptomatic or silent atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation 2003; 107(8): 1141-5.
32. Wolk R, Kulakowski P, Karczmarewicz S, et al. The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. Int J Cardiol 1996; 54(3): 207-11.
33. Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett EL; Azimilide Supraventricular Arrhythmia Program Investigators. Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. Am Heart J 2003; 146(3): 489-93.
34. Rho RW, Page RL. Asymptomatic atrial fibrillation. Prog Cardiovasc Dis 2005; 48(2): 79-87.
35. Ziegler PD, Koehler JL, Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm 2006; 3(12): 1445-52.
36. Camm AJ, Evans KE, Ward DE, Martin A. The rhythm of the heart in active elderly subjects. Am Heart J 1980; 99(5): 598-603.
37. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96(7): 2455-61.
38. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74(3): 236-41.
39. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987; 317(11): 669-74.
40. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271(11): 840-4.
41. Roche F, Gaspoz JM, Da Costa A, et al. Frequent and prolonged asymptomatic episodes of paroxysmal atrial fibrillation revealed by automatic long-term event recorders in patients with a negative 24-hour Holter. Pacing Clin Electrophysiol 2002; 25(11): 1587-93.
42. Defaye P, Dournaux F, Mouton E. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance. Pacing Clin Electrophysiol 1998; 21(1 Pt 2): 250-5.
43. Swerdlow CD, Schsls W, Dijkman B, et al. Detection of atrial fibrillation and flutter by a dual-chamber implantable cardioverterdefibrillator. For the Worldwide Jewel AF Investigators. Circulation 2000; 101(8): 878-85.
44. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22(8): 983-8.
45. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996; 27(10): 1760-4.
46. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36(6): 1115-9.
47. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146(12): 857-67.
48. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347(23): 1825-33.
49. Flaker GC, Belew K, Beckman K, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149(4): 657-63.
50. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366(2): 120-9.
51. Oral H, Veerareddy S, Good E, et al. Prevalence of asymptomatic recurrences of atrial fibrillation after successful radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2004; 15(8): 920-4.
52. Vasamreddy CR, Dalal D, Dong J, et al. Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter ablation. J Cardiovasc Electrophysiol 2006; 17(2): 134-9.
53. Klemm HU, Ventura R, Rostock T, et al. Correlation of symptoms to ECG diagnosis following atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2006; 17(2): 146-50.
54. Hindricks G, Piorkowski C, Tanner H, et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005; 112(3): 307-13.
55. Saririan M, Eisenberg MJ. Myocardial laser revascularization for the treatment of end-stage coronary artery disease. J Am Coll Cardiol 2003; 41(2): 173-83.
56. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293(21): 2634-40.
57. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 2006; 48(11): 2340-7.
58. Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008; 118(24): 2498-505.
59. Stabile G, Bertaglia E, Senatore G, et al. Feasibility of pulmonary vein ostia radiofrequency ablation in patients with atrial fibrillation: a multicenter study (CACAF pilot study). Pacing Clin Electrophysiol 2003; 26(1 Pt 2): 284-7.
60. Kottkamp H, Tanner H, Kobza R, et al. Time courses and quantitative analysis of atrial fibrillation episode number and duration after circular plus linear left atrial lesions: trigger elimination or sub strate modification: early or delayed cure? J Am Coll Cardiol 2004; 44(4): 869-77.
61. Dagres N, Kottkamp H, Piorkowski C, et al. Influence of the duration of Holter monitoring on the detection of arrhythmia recurrences after catheter ablation of atrial fibrillation: implications for patient follow-up. Int J Cardiol 2010; 139(3): 305-6.
62. Senatore G, Stabile G, Bertaglia E, et al. Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation. J Am Coll Cardiol 2005; 45(6): 873-6.
63. Piorkowski C, Kottkamp H, Tanner H, et al. Value of different follow-up strategies to assess the efficacy of circumferential pulmonary vein ablation for the curative treatment of atrial fibrillation. J Cardiovasc Electrophysiol 2005; 16(12): 1286-92.
64. Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011; 57(2): 160-6.
65. Sorgente A, Tung P, Wylie J, Josephson ME. Six year follow-up after catheter ablation of atrial fibrillation: a palliation more than a true cure. Am J Cardiol 2012; 109(8): 1179-86.
66. Martinek M, Aichinger J, Nesser HJ, Ziegler PD, Purerfellner H. New insights into long-term follow-up of atrial fibrillation ablation: full disclosure by an implantable pacemaker device. J Cardiovasc Electrophysiol 2007; 18(8): 818-23.
67. Bertaglia E, Tondo C, De Simone A, et al. Does catheter ablation cure atrial fibrillation? Single-procedure outcome of drugrefractory atrial fibrillation ablation: a 6-year multicentre experience. Europace 2010; 12(2): 181-7.
68. Ouyang F, Tilz R, Chun J, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year followup. Circulation 2010; 122(23): 2368-77.
69. Tzou WS, Marchlinski FE, Zado ES, et al. Long-term outcome after successful catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3(3): 237-42.
70. Seidl K, Meisel E, Van Agt E, et al. Is the atrial high rate episode diagnostic feature reliable in detecting paroxysmal episodes of atrial tachyarrhythmias? Pacing Clin Electrophysiol 1998; 21(4 Pt 1): 694-700.
71. Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009; 30(21): 2631-71.
72. Hindricks G, Pokushalov E, Urban L, et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: Results of the XPECT trial. Circ Arrhythm Electrophysiol 2010; 3(2): 141-7.
73. Hanke T, Charitos EI, Stierle U, et al. Twenty-four-hour holter monitor follow-up does not provide accurate heart rhythm status after surgical atrial fibrillation ablation therapy: up to 12 months experience with a novel permanently implantable heart rhythm monitor device. Circulation. 2009; 120(11 Suppl): S177-84.
74. Eitel C, Husser D, Hindricks G, et al. Performance of an implantable automatic atrial fibrillation detection device: impact of software adjustments and relevance of manual episode analysis. Europace 2011; 13(4): 480-5.
75. Pokushalov E, Romanov A, Corbucci G, et al. Use of an implantable monitor to detect arrhythmia recurrences and select patients for early repeat catheter ablation for atrial fibrillation: a pilot study. Circ Arrhythm Electrophysiol 2011; 4(6): 823-31.
76. Arya A, Piorkowski C, Sommer P, Kottkamp H, Hindricks G. Clinical implications of various follow up strategies after catheter ablation of atrial fibrillation. Pacing Clin Electrophysiol 2007; 30(4): 458-62.